

Patent  
030639.0034.CPA2

C1  
18. (Amended) A method of treating insulin-requiring diabetes mellitus in a mammal comprising administering to said mammal an effective amount of an insulin and an effective amount of a glucagon-like peptide 1 (7-36) amide analogue, wherein said glucagon-like peptide 1 (7-36) amide analogue is administered orally.

3  
17. (Amended) A method according to claim <sup>2</sup>16 wherein said insulin and said glucagon-like peptide 1 (7-36) amide analogue are administered to the human at a selected time prior to ingestion of a meal.

C2  
4  
18. (Amended) A method according to any of claims <sup>1-3</sup>15-17 wherein said glucagon-like peptide 1 (7-36) amide analogue is a glucagon-like peptide 1 (7-37).

5  
19. (Amended) A method according to any of claims <sup>1-3</sup>15-17 wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-36) amide.

6  
20. (Amended) A method of treating insulin-requiring diabetes mellitus in a mammal comprising administering an effective amount of a glucagon-like peptide 1 (7-36) amide analogue wherein said glucagon-like peptide 1 (7-36) amide analogue is administered orally.

C3  
8  
22. (Amended) A method according to claim <sup>7</sup>21 wherein said glucagon-like peptide 1 (7-36) amide analogue is administered to the human at a selected time prior to ingestion of a meal.

9  
23. (Amended) A method according to any of claims <sup>6-8</sup>20-22 wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-37).

10  
24. (Amended) A method according to any of claims <sup>6-8</sup>20-22 wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-36) amide.

Patent  
030639.0034.CPA2

C3  
11  
25. (Amended) A method of treating insulin-requiring diabetes mellitus in a mammal comprising administering to said mammal an effective amount of an insulin and an effective amount of a glucagon-like peptide 1 (7-36) amide analogue, wherein said glucagon-like peptide 1 (7-36) amide analogue is administered nasally.

13  
27. (Amended) A method according to claim <sup>12</sup>~~26~~ wherein said insulin and said glucagon-like peptide 1 (7-36) amide analogue are administered to the human at a selected time prior to ingestion of a meal.

C4  
14  
28. (Amended) A method according to any of claims <sup>11-13</sup>~~25-27~~ wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-37).

15  
29. (Amended) A method according to any of claims <sup>11-13</sup>~~25-27~~ wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-36) amide.

16  
30. (Amended) A method of treating insulin-requiring diabetes mellitus in a mammal comprising administering an effective amount of a glucagon-like peptide 1 (7-36) amide analogue, wherein said glucagon-like peptide 1 (7-36) amide analogue is administered nasally.

18  
32. (Amended) A method according to claim <sup>17</sup>~~31~~ wherein said glucagon-like peptide 1 (7-36) amide analogue is administered to the human at a selected time prior to ingestion of a meal.

C5  
19  
33. (Amended) A method according to any of claims <sup>16-18</sup>~~30-32~~ wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-37).

20  
34. (Amended) A method according to any of claims <sup>16-18</sup>~~30-32~~ wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-36) amide.

Please enter new claims 35-39 as follows.

Patent  
030639.0034.CPA2

<sup>21</sup>  
~~35~~. (New) A method of treating insulin-requiring diabetes in a mammal comprising administering to the mammal an effective amount of a peptide selected from the group consisting of

- (a) glucagon-like peptide 1 (7-37);
- (b) glucagon-like peptide 1 (7-36) amide; and
- (c) an effective fragment or analogue of (a) or (b).

Sub E 17 36. (New) The method of claim ~~48~~ further comprising administering an insulin.

16 <sup>23</sup>  
~~37~~. (New) A method of treating insulin-requiring diabetes in a mammal comprising administering to the mammal an effective amount of a glucagon-like peptide 1-related peptide.

Sub E 27 38. (New) The method of claim ~~50~~ further comprising administering an insulin.

<sup>25</sup>  
~~39~~. (New) The method according to any of claims <sup>6 16 21 23</sup> ~~20, 30, 35~~ or ~~31~~ wherein the insulin-requiring diabetes is Type I diabetes.--

#### REMARKS

Claims 15-39 are pending in the instant application. Claims 35-39 have been added, and find full support in the specification, as do the amendments to the existing claims. For example, amendments to to all claims are supported on page 2, lines 1-12. Claims 35 and 36 also find support on page 2, lines 1-23 of the specification, claim 38-38 find support on page 4, lines 26-30, and claim 39 finds support on page 6, lines 19-34. These claims add no new matter, and Applicant respectfully requests their entry.

Claims 15-34 stand rejected under 35 USC §112, paragraph 1 and the judicially created doctrine of obviousness-type double patenting. Applicant thanks the Examiner